Form D · Pharmaceuticals
Trieza Therapeutics, Inc.
Cambridge, MA · CIK 0001691194
Offering snapshot reported Dec 5, 2016 · SEC filing
- Reported sold
- $1 Offering amount: $1
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 21, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 5, 2016 | Initial | $1 | No comparison | 5 | SEC filing |
| Dec 5, 2016 | Initial | $5,999,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-275660
The Company issued shares of its capital stock to Potenza Therapeutics, Inc. ("Potenza"), its former parent company, which distributed the shares as a dividend to certain Potenza shareholders in connection with the spin-out of the Company from Potenza.
Source: Form D, filed Dec 5, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Cordo | Executive |
| Luke Evnin | Director |
| Daniel Hicklin | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1030 Massachusetts Avenue Suite 210
Cambridge, MA, 02138
Cambridge, MA, 02138